KMDA Q4 2024 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$520M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$39M+7.1% YoY

Gross Profit

$17M43.7% margin

Operating Income

$5M13.0% margin

Net Income

$4M9.8% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-6.6%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$7M

Stock-Based Comp.

$174,000

Balance Sheet

Total Assets

$372M

Total Liabilities

$113M

Stockholders' Equity

$259M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$36M	+7.1%
Gross Profit	$17M	$14M	+18.2%
Operating Income	$5M	$3M	+82.9%
Net Income	$4M	$5M	-24.7%